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The first description of posterior urethral valves (PUVs) was made 
by  Hugh  Hampton  Young.  PUVs  represent  a  spectrum  of  severity, 
ranging from disease incompatible with postnatal life to disease that is 
minimal  and  may  not  manifest  until  later  in  life.  Treatment  of  PUVs 
remains a clinical challenge, requiring active management from infancy 
into adulthood to avoid progressive dysfunction and deterioration of both 
the upper and lower urinary tracts.
Pathophysiology
During embryogenesis, the most caudal end of the Wolffian duct is 
absorbed into the primitive cloaca at the site of the future verumontanum 
in the posterior urethra. In healthy males, the remnants of this process are 
the  posterior  urethral  folds,  called  plicae  colliculi.  Histological 
studies suggest  that  PUVs  are  formed at  approximately  4 weeks' 
gestation, as the Wolffian duct fuses with the developing cloaca.
Young popularized a  classification  of  PUV[1]  Abnormally  high 
insertion  and  fusion  of  these  primitive  folds  were  believed  to  be  the 
origins  of  95%  of  PUVs;  this  type was referred  to  as  type  I 
PUVs. Although Young described type II PUVs, most pediatric urologists 
believe that these are not obstructing valves but simply hypertrophy of 
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the plicae colliculi. Also described by Young, type III PUVs constitute a 
septum at the junction of the posterior and anterior urethra, instead of a 
sail-like valve. Type III PUVs are believed to originate from incomplete 
dissolution of the urogenital membrane. This classification has no clinical 
value and is now considered outdated.
Congenital obstructing posterior urethral membrane (COPUM) was 
first proposed by Dewan and Goh and was later supported by histological 
studies by Baskin [2] This concept proposes that, instead of a true valve, a 
persistent oblique membrane is ruptured by initial catheter placement and, 
secondary to rupture, forms a valvelike configuration. 
PUV represents a spectrum of severity. The degree of obstruction 
caused by this abnormality widely varies depending on the configuration 
of the obstructive membrane within the urethra. The morbidity of PUVs 
is  not  merely  limited  to  transient  urethral  obstruction;  however,  the 
congenital  obstruction  of  the  urinary  tract  at  a  critical  time  in 
organogenesis may  have  a  profound  and  lifelong  effect  on  kidney, 
ureteral and bladder function.
Renal insufficiency is caused by PUVs in approximately 10-15% of 
children  undergoing  renal  transplant,  and  approximately  one  third  of 
patients born with PUVs progress to end-stage renal disease (ESRD).
Moreover, children with PUVs develop thickened bladders because 
of  increased  collagen  deposition  and  muscle  hypertrophy  within  the 
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bladder wall.  Hypertrophy and hyperplasia of  the detrusor  muscle and 
increases in connective tissue decrease bladder compliance during filling. 
Bladder emptying occurs with high intravesical pressures, which can be 
transmitted to the ureters and kidneys. These patients are susceptible to 
incontinence, infection and progressive renal damage.
Frequency
PUV is the most common cause of lower urinary tract obstruction 
in male neonates; the reported incidence is 1 per 8,000 to 1 per 25,000 
live births.
Mortality/Morbidity
PUVs are the cause of renal insufficiency in approximately 10-15% 
of children undergoing renal transplant, and approximately one third of 
patients born with PUV progress to ESRD.
Sex
PUVs  exclusively  occur in  males.  The  homolog  to  the  male 
verumontanum from which the valves originate is the female hymen.
Age
Diagnosis is usually made before birth or at birth when a boy is 
evaluated  for  antenatal  hydronephrosis.  Before  the  era  of  prenatal 
ultrasonography, PUVs were discovered during evaluation of urinary tract 
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infection (UTI), voiding dysfunction, or renal failure. Although rare, adult 
presentation of PUVs has been described in case reports, with symptoms 
varying from obstructive voiding symptoms to postejaculatory dysuria. In 
the presonography era, late presentation of PUV was considered a good 
prognostic sign suggestive of a lesser degree of obstruction.
Clinical
History
• Prenatal diagnosis 
o The  widespread  use  of  antenatal  ultrasonography  and  the 
sophisticated  neonatal  care  available  in  most  developed 
countries has enabled diagnosis of posterior urethral valves 
(PUVs) in many individuals in the prenatal timeframe. 
o Diagnosis is usually made before or at birth when a boy is 
evaluated for antenatal hydronephrosis. 
o In 1989, Thomas reported that 10% of patients with prenatal 
hydronephrosis detected by ultrasonography had PUV[3]
o Despite widespread use of antenatal ultrasonography, some 
patients with PUVs present later in life. 
o In a 1993 report,  Dinneen et al  reported the sensitivity of 
antenatal ultrasonography to be only 45% in detecting PUVs 
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in 45 patients who presented when younger than 6 month[4]. 
With  improvements  in  technology,  the  sensitivity  has 
increased over the last 10 years. 
o Those  patients  with  PUVs  not  diagnosed  on  prenatal 
ultrasonography  and  who  do  not  manifest  overt  urinary 
pathology are at risk of delayed presentation of PUVs.
• Delayed presentation 
o UTI, diurnal enuresis in boys older than 5 years, secondary 
diurnal enuresis, voiding pain or dysfunction, and decreased 
force of stream may indicate the presence of PUV[5]
o PUVs  are  sometimes  discovered  during  evaluation  of 
abdominal mass or renal failure.
• Incidental  diagnosis:  Hydronephrosis  or  proteinuria found  on 





Most patients have normal findings upon physical examination. When 
present, abnormal physical findings are the result of severe renal 
insufficiency.
• Neonates may present with severe pulmonary distress due to 
underdevelopment of the lung caused by oligohydramnios. An 
appropriate volume of amniotic fluid (produced by the kidneys) is 
necessary for complete and proper branching of the bronchial tree 
and alveoli. Physical findings can include the following: 
o Poor fetal breathing movements 
o Small chest cavity 
o Abdominal mass (ascites) 
o Potter facies 
o Limb deformities (skin dimpling) 
o Indentation of the knees and elbows due to compression 
within the uterus
• In  older  children,  physical  findings  can  include  poor  growth, 
hypertension, and lethargy. An intermittent or weak urinary stream 
is a nonreliable sign.
Causes
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PUV is a congenital obstruction caused by a malformation of the 
posterior  urethra.  The  significance  of  this  obstruction  depends  on  the 
secondary effects on the bladder, ureters, and kidneys.
• Type I PUV: This type of obstruction is believed to be secondary to 
abnormal insertion and absorption of the most distal aspects of the 
Wolffian ducts during bladder development. In the healthy male, 
the remnants of these ducts are observed as the plicae colliculi. 
• Type III PUV: These valves are observed as a membrane in the 
posterior urethra believed to originate from incomplete canalization 
between the anterior and posterior urethra.
• RISK FACTORS
I. Antenatal diagnosis <24wks of gestation 
Antenatal USG features of PUV
1.Bilateral hydroureteronephrosis 
2.Distended bladder






II. Age at diagnosis <1year
III. Bilateral VUR 
IV.Urinary incontinence beyond 5years of age
V. Renal parenchymal damage detected by USG
• Hyperechoiec kidney
• No pyramids seen
VI. Serum creatinine >0.8mg/dl during Ist year of age.
VII. Persistence of dilated system after relief of obstruction
VIII. Recurrent UTI 
IX. Timing of relief of obstruction >1year of age
X. Absent Pop – off Mechanisms
• unilateral VUR
• Urinary ascites 
• Peri renal urinoma 
• Large bladder diverticula 
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• Immediately following birth, the infant's serum chemistries are the 
same as the mother's. Therefore, serum values for creatinine and 
BUN should be obtained at least 24 hours after birth. In utero, the 
placenta functions as the major blood filter for the fetus, with waste 
passed on to the mother. Observing serum chemistries for several 
days  to  weeks  is  important  to  determine  the  true  status  of  the 
newborn's renal function. 
• The normal newborn kidney is still undergoing maturation at birth, 
and infant glomerular filtration rate (GFR) continues to improve 
during the first several months of life. Because of renal immaturity 
at  birth,  the  newborn  is  unable  to  concentrate  urine  and  is 
susceptible  to  dehydration.  This  defect  is  exacerbated  by  renal 
dysplasia such as that found with posterior urethral valves (PUVs). 
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• As  renal  maturation  continues,  the  serum  creatinine  clearance 
normally  improves.  If  significant  renal  dysplasia  or  damage has 
occurred, the serum creatinine fails to reach a normal level during 
the first year of life. Serum creatinine levels greater than 0.8 mg/dL 
during the first year of life have been demonstrated to be associated 
with poor long-term renal function.
Imaging Studies
• Renal and bladder ultrasonography 
o Every child with antenatal hydronephrosis requires renal and 
bladder ultrasonography assessment in the immediate postnatal 
period.  Focus  should  be  directed  towards  appearance  of  the 
renal  parenchyma,  evidence  of  renal  collecting  system 
dilatation, bladder wall thickness, and presence of ascites. 
o Because  newborns  commonly  have  relative  hypovolemia 
during  the  first  few  days  of  life, perform 
repeat ultrasonography after the first  week of life if previous 
findings  were  normal  in  a  child  with  previously  diagnosed 
antenatal hydronephrosis before making a final determination 
that the hydronephrosis has resolved.
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• Voiding cystourethrography 
o The  key  to  the  workup  of  any  child  with  antenatal 
hydronephrosis  is  voiding  cystourethrography  (VCUG). 
Perform VCUG during voiding and under fluoroscopy, with 
imaging of the posterior urethra. 
o The diagnosis of PUV is indicated by visualization of the 
valve leaflets. Other clues to the diagnosis are a thickened 
trabeculated bladder, a dilated or elongated posterior urethra, 
and  a  hypertrophied  bladder  neck.  Diverticula,  cellules, 
vesicoureteral  reflux,  and reflux into the ejaculatory ducts 
secondary  to  elevated  bladder  and  urethral  pressures  may 
also be present.
• Renal scintigraphy 
o Although  not  necessary  in  every  child,  renal  scintigraphy 
may be helpful in some cases. It should not be performed in 
the neonatal period because renal immaturity does not allow 
for accurate estimation of renal function. If renal dysplasia is 
suspected,  nuclear  imaging  can  determine  relative  renal 
function. Some children may have secondary ureterovesical 
junction obstruction due to bladder hypertrophy. 
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o Tc-dimercaptosuccinic  acid  (DMSA),  glucoheptonate,  and 
mercaptoacetyl  triglycine  (MAG-3)  renal  scintigraphy  are 
cortical  imaging  studies  that  provide  information  about 
relative renal function (each kidney relative to the other) and 
intrarenal function (eg, photopenic areas within the kidney 
indicate  scarring  or  dysplasia).  Additionally,  the  MAG-3 
renal  scan  with  furosemide  (Lasix)  provides  information 
about renal drainage and possible obstruction.
Other Tests
• Urodynamic evaluation provides information about bladder storage 
and  emptying.  The  mature  bladder  should  store  urine  at  a  low 
pressure and then completely empty at appropriate pressures. 
• The term "valve bladder" is used to describe patients with PUV and 
a  fibrotic  noncompliant  bladder.  These  patients  are  at  risk  of 
developing hydroureteronephrosis, progressive renal deterioration, 
recurrent infections, and urinary incontinence. 
• Patients with PUV require periodic urodynamic testing throughout 




• Cystoscopy  serves  both  diagnostic  and  therapeutic  functions  in 
these infants. Appropriately-sized cystoscopes (<8F) are needed to 
avoid injury to the urethra. 
o Diagnostic  cystoscopy:  Confirmation  with  cystoscopy  is 
required  in  every  child  in  whom  PUV  is  suggested  after 
VCUG. In some, the filling defect  observed on VCUG may 
represent only external sphincter contraction during voiding. In 
others, the valve leaflets are confirmed. 
o Therapeutic  cystoscopy  (ie,  transurethral  incision  of  the 
PUVs): Multiple techniques have been described for ablating 
the valves. Disruption of the obstructing membrane by blind 
passage  of  a  valve  hook  is  now  only  of  historic  interest. 
Currently,  valves  are  disrupted  under  direct  vision  by 
cystoscopy  using  an  endoscopic  loop,  Bugbee 
electrocauterization,  or  laser  fulguration.  The objective  is  to 
relieve the obstruction by cutting the valves at the 12-, 5-, and 
7-o'clock positions. Perform this in the least traumatic fashion 
to avoid secondary urethral stricture or injury to the urethral 
sphincter mechanism.
• In some patients,  the urethra may be too small for the available 
cystoscopic  instrumentation.  Fortunately,  because  of  continued 
21
21
advancements  in  pediatric  endoscopic  equipment,  this  is  an 




The  medical  management  of  posterior  urethral  valves  (PUVs) 
relates to the treatment of the secondary effects of the valves. Adequate 
care  involves  a  team  approach  that  includes  a  neonatologist,  general 
pediatrician,  pediatric  urologist,  and  pediatric  nephrologist.  Short-term 
goals  involve treating  pulmonary  distress,  immediate  relief  of  urethral 
obstruction  (placement  of  5F  feeding  tube),  and  fluid  and  electrolyte 
management. In children who survive the pulmonary distress, the long-
term  issues  include  treatment  of  bladder  dysfunction  and  renal 
insufficiency.
• Renal treatment 
o Newborn  period: Few patients  present  with  bilateral  renal 
dysplasia  at  birth.  In  the  past,  if  patients  did  not  die  from 
associated  pulmonary  insufficiency,  they  died  due  to 
progressive  renal  insufficiency.  With  recent  advances  in 
peritoneal dialysis, some children may be treated successfully 
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from birth. If growth is adequate, renal transplantation is often 
possible after the first year of life. 
o Delayed  renal  insufficiency:  Approximately  one  third  of 
patients with PUV progress to ESRD and the need for dialysis 
or  transplantation.  Progression of  ESRD is accelerated at  the 
time of puberty due to the increased metabolic workload placed 
on the kidneys. Growth in these children may be significantly 
below the reference range for the child's age. Adequate caloric 
intake  and  protein  nutrition  are  essential  to  growth  but  may 
also accelerate  the  rise  in  serum  creatinine  levels.  Renal 
dysfunction  can  be  accelerated  by  recurrent  infections  and 
elevated bladder pressures. Treatment of the lower urinary tract 
may influence progression of upper tract disease.
• Bladder management 
o Newborn  period:  All  male  children  with  antenatal 
hydronephrosis  require  VCUG shortly  after  birth  to  exclude 
PUV.  While  awaiting  this  study,  place  a  5F  or  8F  urethral 
catheter to allow for bladder drainage. If valves are confirmed, 
they can be incised within the first few days of life. However, 
the  newborn  urethra  may  be  too  small  to  accommodate 
available equipment. In these individuals, a vesicostomy can be 
performed as  a  temporary solution  until  urethral  growth has 
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been  adequate  to  allow  transurethral  incision.  Secondary 
ureterovesical junction obstruction from bladder hypertrophy is 
a  controversial  issue.  Supravesical  urinary  diversion 
procedures  (eg,  cutaneous  ureterostomies)  are  reserved  for 
patients  who  appear  to  have  ureterovesical  junction 
obstruction. This is very infrequent. 
o Delayed bladder management: Severe or prolonged urethral 
obstruction  can  lead  to  a  fibrotic,  poorly  compliant  bladder. 
This occurs when the developing bladder is exposed to high 
pressures from bladder outlet obstruction, leading to increases 
in  bladder  collagen  deposition  and  detrusor  muscle 
hypertrophy  and  hyperplasia.  These  bladders  manifest  poor 
compliance, leading to elevated storage pressures. This, in turn, 
leads  to  increased risk  of  reflux, hydroureteronephrosis,  and 
urinary  incontinence.  Use  of  urodynamic  testing  to  assess 
bladder compliance help identify patients at risk. Some patients 
may  respond  to  anticholinergic  medication,  such  as 
oxybutynin.  Institution  of  intermittent  clean  catheterization 
may aid some patients achieve continence by preventing the 
bladder from overfilling. In patients who do not gain adequate 
bladder capacity and safe compliance despite optimal medical 
management, augmentation cystoplasty may be required.
Surgical Care
Surgical  care  of  the  patient  with  PUV varies  according  to  age, 
bladder  status,  and  renal  status.  Prenatal  surgery  has  been reported  in 
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patients  diagnosed  with  PUV with  the  goal  of  improving  postnatal 
outcomes. Antenatal  hydronephrosis  is  detectable  only  after  renal 
development  has  occurred and  urine  production  has  started. With 
improvement  in  prenatal  ultrasonography,  the  hope  was  that  earlier 
intervention with vesicoamniotic shunting would improve postnatal renal 
function. However, identification of those patients who may benefit form 
early  intervention  remains  elusive.  To  date,  improvement  in  renal 
function  has  been  difficult  to  demonstrate  and  prenatal  intervention 
remains experimental.
• Urinary drainage 
• Postnatal primary valve ablation 
• Ideal treatment involves transurethral incision of the 
PUV during the first few days of life. 
• Current infant resectoscopes are available in size 8F 
and smaller. 
• The valves can be incised at the 12-, 5-, and 7-o'clock 
positions, with either a cold knife or electrocautery. 
• Some surgeons prefer to leave a catheter in place for 
2-3 days after the procedure. 
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• The  timing  of  the  postoperative  VCUG  varies  and 
ranges from several days to several months. 
• Comparison of posterior urethral diameter to anterior 
urethral  diameter  can provide an objective measure of 
valve ablation. In most patients, the posterior urethra is 
markedly  dilated. Postincision  diameter  should 
decrease.  
• The  normal  posterior-to-anterior  urethral  ratio  is 
approximately 2.3. Approximately two thirds of patients 
have  successful  valve  ablation  with  one  procedure, 
manifested by a postincision ratio of 3.1 or less[6] One 
third of patients require a second incision to achieve this 
level of posterior urethral reduction.
• Vesicostomy:  When  urethral  size  precludes  safe  valve 
ablation, a communicating channel between the bladder and 
lower  abdominal  wall  (ie,  vesicostomy) can be  created  to 
provide  bladder  drainage.  Generally,  an  18-20F  stoma  is 
created  approximately  midway  between  the  pubis  and 
umbilicus in the midline. Take care to bring the dome of the 
bladder to the skin and to limit the stomal size to prevent 
prolapse  of  bladder  urothelium  through  the  vesicostomy. 
However, formation of too small a stoma results in stomal 
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stenosis and inadequate bladder emptying. Too large a stoma 
allows for bladder prolapse. Vesicostomy use has decreased 
because most patients can be safely drained and can undergo 
valve ablation. 
• Cutaneous  ureterostomies:  Bilateral  cutaneous 
ureterostomies  can  also  be  placed  to  provide  for  urinary 
drainage.  Techniques  for  cutaneous  ureterostomy  include 
end stomal ureterostomy, loop ureterostomy, Y-ureterostomy 
(in which the ureter is divided and one end is brought to the 
skin  and  the  other  is  reanastomosed  in  a  uretero-
ureterostomy),  and ring ureterostomy techniques.  Potential 
complications of  cutaneous ureterostomies include ureteral 
devascularization, inadequate drainage, and stomal stenosis. 
These are rare.
• Secondary bladder surgery 
• Augmentation cystoplasty 
• Indications  for  bladder  augmentation  include 
inadequately  low  bladder  storage  volumes  and  high 
bladder pressures despite anticholinergic medication and 
clean intermittent catheterization. 
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• The  ileum is  most  commonly  used;  however,  large 
bowel, stomach, and ureter are also used, depending on 
clinical conditions and surgeon preference. 
• Before  undertaking the  augmentation  procedure,  the 
implications of bladder augmentation should be carefully 
reviewed with parent  and family.  Augmentation  should 
only be offered to patients willing to commit to lifelong 
intermittent catheterization. 
• Potential  complications  include  bladder 
rupture (approximately  10%  of  patients);  electrolyte 
disturbances, which may be worsened by the placement 
of intestinal mucosa in contact with urine, especially in 
those with a serum creatinine greater than 2 mg/dL; and 
mucus  production,  which can  be  a  source  of  catheter 
blockage and may be a nidus for stone formation.  
• The future risk of neoplasia has not yet been defined 
in  these  patients,  but  several  cases  of  malignant 
degeneration in augmented bladder have been reported. 
Despite  these  risks,  augmentation  can  significantly 
improve patient  lifestyle  in  those  who have intractable 
incontinence  due  to  poor  compliance  and  bladder 
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overactivity.  By  lowering  intravesical  pressures,  the 
upper urinary tract may also be protected.
• Continent  appendicovesicostomy:  Also  called  the 
Mitrofanoff technique, this procedure involves placement of 
a  nonrefluxing tubular  conduit  for  catheterization between 
the bladder and skin to provide an alternative channel for 
catheterization.  In  children  with  PUVs,  institution  of 
intermittent catheterization through a sensate urethra can be 
difficult. In addition, some patients may have a very dilated 
proximal urethra which may not be easily catheterized. The 
stoma  often  can  be  hidden  in  the  umbilicus  to  provide 
acceptable cosmesis.  The appendix, ureter,  and tubularized 
bowel can be used for formation of this channel.
Consultations
The child with PUV is best cared for using a team approach.
• Pediatrics and neonatology 
o The most life-threatening problem in the newborn period is 
the  potential  pulmonary  hypoplasia  related  to  in  utero  renal 
dysfunction. This may be associated with oligohydramnios. At 




o Upon birth, new metabolic demands are made on the infant 
kidneys. 
o Urinary stasis and elevated detrusor pressures are risk factors 
for urosepsis in the newborn. 
o Generally,  treatment  is  coordinated  best  by  establishing  a 
primary pediatrician or pediatric service to coordinate further 
referrals. 
o Additional pediatric subspecialty consultations often include 
a neonatal intensivist, a pediatric nephrologist, and a pediatric 
urologist.
• Radiology 
o Establishing  the  diagnosis  is  a  priority  in  the  newborn 
period. 
o Obtain VCUG with proper views of the posterior urethra. 
o Other  required  studies  include  a  renal  sonography and,  at 
times, renal scintigraphy.
• Urology 
o In  the  newborn  period,  the  first  treatment  intervention  is 
achieving bladder drainage. Catheterization may be difficult or 
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even  impossible  because  of  the  thickness  of  the  valves  or 
dilation of the posterior urethra with a hypertrophied bladder 
neck.  Cystoscopic  visualization  with  incision  of  the  valves 
should be accomplished in the first few days of life once the 
child is metabolically stable. 
o After  the  initial  newborn  period  and  successful  bladder 
drainage,  either  by  valve incision  or  vesicostomy,  long-term 
urologic  care  is  needed.  Renal  deterioration  secondary  to 
progressive bladder dysfunction should be a primary goal and 
requires follow-up care with serial renal ultrasonographic and 
bladder urodynamic studies. Management is based on clinical 
findings,  ranging  from  annual  imaging  to  pharmaceutical 
management to bladder reconstruction.
Diet
Dietary restrictions depend on renal status.
• Avoiding  progression  of  renal  deterioration  while  supporting 
growth requires careful regulation of protein intake, which is best 
managed under the care of a pediatric nephrologist. 





Unless complications such as renal insufficiency occur, activity can 
generally remain unrestricted. Urinary incontinence may present a social 
barrier. This can often be managed with anticholinergic therapy with or 
without clean intermittent catheterization.
Medication
Posterior  urethral  valves  (PUVs)  initially  represent  a  surgical 
condition. However, long-term treatment often comprises a combination 
of medical and surgical treatment, primarily directed at the bladder. The 
primary medications involved in bladder management are anticholinergic 
medications used to improve bladder compliance. Other medications that 
may  be  needed  include  prophylactic  antibiotics  and  medications  for 
management of renal insufficiency.
Anticholinergic agents
These agents are used to improve bladder capacity and compliance 




Inexpensive and effective, oxybutynin chloride long has been the 
first-line anticholinergic. By inhibiting muscarinic action of acetylcholine 
on smooth  muscle,  exerts  antispasmodic  effect  on  bladder  muscle.  Its 
nonselective anticholinergic action increases adverse effects; however, it 
may produce fewer adverse effects if dosing is gradually increased over 
>2 wk. Available in both 5-mg tab and 5-mg/5-mL elixir. A long-acting 
10-mg  tab  with  once-a-day  dosing  was  recently  introduced  but  is 
expensive and has been approved only for adults.
Hyoscyamine sulfate
Works  by  inhibiting  postganglionic  cholinergic  receptors  on 
smooth muscle cells. Rapidly absorbed and distributed throughout body, 
including  across  blood-brain  barrier.  Half-life  is  3.5  h;  excreted 
unchanged in urine. Available in PO, IV, and SL forms; tab generally used 





A new antimuscarinic  drug with  more  selective  receptor  profile 
targeted for detrusor smooth muscle. Used extensively in adults but not 
approved by FDA for children. In adults, demonstrated equal in efficacy 
to oxybutynin chloride with significantly fewer adverse effects. Available 
in 1- and 2-mg tab.
Antibiotics
Patients with history of recurrent UTI may benefit from antibiotic 
prophylaxis, especially in the presence of vesicoureteral reflux. The ideal 
antibiotic for urinary prophylaxis is safe, effective, inexpensive, and has 
no adverse effects. Although no antimicrobial is ideal, some are preferred 
in children. Prophylactic dosage is usually one quarter of the therapeutic 
dose administered once per day. Too high a dose increases adverse effects 
(eg, GI upset) and may alter fecal flora. More appropriate antibiotics in 
children  include  trimethoprim  (TMP),  sulfamethoxazole  (SMZ), 
nitrofurantoin, and amoxicillin.
Trimethoprim and sulfamethoxazole 
Inhibits  bacterial  growth  by  inhibiting  synthesis  of  dihydrofolic 
acid. TMP alone or in combination with SMZ is the most commonly used 
antibiotic for both treatment and prophylaxis of UTI. Inexpensive and has 
minimal adverse effects on bowel and vaginal flora because excreted and 
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concentrated in urine. Pediatric susp (40 mg TMP and 200 mg SMZ per 5 
mL) available.
Nitrofurantoin 
Synthetic  nitrofuran  that  interferes  with  bacterial  carbohydrate 
metabolism  by  inhibiting  acetylcoenzyme  A.  Bacteriostatic  at  low 
concentrations (5-10 mcg/mL) and bactericidal at higher concentrations.
Another common prophylactic antimicrobial agent, which is also excreted 
in urine, allowing urinary levels to be high while having few effects on 
fecal flora. Inexpensive and comes in both liquid and tab preparations. 
Rarely,  associated  with  peripheral  neuropathy  and  pulmonary 
hypersensitivity. SR formulation available; liquid susp (25 mg/5 mL) also 
available.
Amoxicillin 
Interferes with synthesis of cell wall mucopeptides during active 
multiplication,  resulting  in  bactericidal  activity  against  susceptible 





Kukreja RA et al in Nadiad (Muljibhai Patel Urological Hospital) 
studies  retrospectively  about  70  children  with  PUV  over  last  10yrs. 
Factors found to be statistically significant with a P value < 0.05 were age 
at  intervention  >2  years,  recurrent  urospesis,  B/L  high  grade  VUR, 
bilateral parenchymal damage as seen on USG and nadir serum creatinine 
of > 0.8mg percent.
Oliveira Eduardo A et al in Bresil studied 22 children with PUV to 
identify  the  prognostic  factors;  Oligohydramnios  (p=0.02),  ventilatory 
support (p=0.01), Bilateral VUR(p=0.02), urea>40mg/dl were identified 
as adverse factors. 
Lopez  Pereira  P et  al  espagne studied  40 patients  with  PUV in 
retrospective study and B/L VUR, Creatinine levels, renal echo genicity 
associated with poor prognosis.
R  Lal  et  al  in  AIIMS studied  the  long  term prognosis  of  renal 
function in PUV found to have raised creatinine value in 53% patients at 
presentation and 22.5% eventually progressed to CRF . persistent high 
creatinine,  B/L VUR, persistent  upper  tract   dilatation after  treatment, 
voiding dysfunction and delayed presentation are predictors of poor renal 
function.
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B Duel et al found that increased cortical echogenicity & loss of 
corticomedullary differentiation are associated with poor renal outcome. 
Rittenberg  MH  et  al  studied  the  protective  factors(‘’pop-off’’ 
mechanism)found 1)VURD syndrome, 2)bladder diverticula, 3) urinary 
ascites are associated with better preservation of renal  function.
Parkhouse HF et al found that bad outcome is associated with early 
presentation, B/L VUR and day time incontinence after 5 years.
De  Foor  W et  al  found  that  increased  nadir  creatinine  level  & 
bladder dysfunction are independent risk factors for ESRD(OR 71&8.9).
Elisa Ylinen et al found high nadir serum creatinine level during 1st 
yr(p<0.001),  B/L  VUR(p<0.05)  and  breakthrough  UTIs(p<0.05)  are 
associated with poor outcome. Also found that no significant difference in 
outcome between AN & post natal detection of PUV.
Vincent C. Onuora et al studied high serum creatinine level after 





PUV  present  with  various  clinical  manifestations.  This  study 
review to identify  the prognostic  factors  and help in  defining the  end 
result and implicating the correct treatment protocol.
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AIM OF THE STUDY 
To study the  risk factors for chronic renal failure in children with 
posterior urethral valve in a tertiary care hospital. 
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MATERIALS AND METHODS 
Study Design: Case Control Study.
Place of  study:  Institute  of  child  health  & hospital  for  children, 
egmore, Chennai - 08.
Study Population:  children diagnosed to have PUV are included in 
this study.  
CASES: PUV patients  with Chronic Renal Failure
CONTROLS: PUV patients without CRF
Sample Size: 72 patients (Sep 2007-  Sep 2009).
MANOEUVRE :
This study is conducted in nephrology and urology departments. 
All  patients  with  PUV  are  studied  by  using  proforma.  Noted  about 
antenatal oligohydramnios and ultrasonogram report. History suggestive 
of PUV like stream disturbances, dribbling, dysuria, straining are asked 
and noted. 
Weight and height of the child was noted.  Clinical  findings like 
pallor, bony abnormalities(genu valgum), palpable bladder, renal masses 
and ascites noted. Blood pressure is measured in all  cases.  Nutritional 
status of the child was assessed and noted. 
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Age  at  diagnosis  was  noted  and  classified  as  whether  it  was 
detected  antenatal,  newborn,  infancy  or  more  than  1  year.  Timing  of 
surgery(relief of obstruction) was noted and classified as < 1 year or > 1 
year.  Surgery  details  like  type  of  surgery,  complications  are  noted. 
Urinary  tract  infections  if  any  number  of  episodes  in  1  year  noted. 
Recurrent UTI was considered when there are 3 or more episodes. 
Investigations  hemoglobin,  urine  routine,  urine  C/S,   urea, 
creatinine and electrolytes,  USG abdomen, MCU and cystoscopy done 




Total  No.  of  study  patients  with  PUV.  72 Patients  with  chronic 
renal  failure  43  (59.7%)  Patients  without  chronic  renal  failure  29 
(40.3%).
Among patients presenting with PUV fever (76.4%) and dysuria 
(63.9%) are the common presentation. 
Among  patient  with  PUV  CRF  43  patients  in  (59.7%),  &  29 
patients without CRF (40.3%). All are boys. 
Other  common  presentation  include  stream  disturbances  in  32 
patients (44.4%) dribbling in 30 patients (41.7%), refusal of feeds in 11 
(15.3%) & vomiting in 24 (33.3%).
Other less common presentation include abdominal distention in  
5  patients  (6.9%),  constipation  in  7  patients  (9.7%),  hematuria  in  5 
patients (6.9%) hesitancy in 4 (5.6%).
Age of presentation ranging from 2 days to 12 years with a mean 
age of 5.9 year.
Earlier  age  of  presentation  usually  associated  with  stream 
disturbances and later  age usually  associated with urinary  infection & 
incontinence.
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Among clinical features, pallor was present in 48 patients (66.7%) 
with PUV hypertension was present in 26 patients (36.1%).
Palpable  bladder  was  present  in  11  patients  (15.3%),  bony 
abnormalities was present in 15 patients with PUV (20.8%). 
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PUV  was  diagnosed  in  various  ages.  In  this  study,  antenatal 
diagnosis was in 6 patients (8.3%) New born 17 patients (23.6%), infancy 
36 patients (50%) more than 1 year 13 patients (18.1%).
Table. 1 
Age of Diagnosis Frequency Percentage
Antenatal 6 8.3
New Born 17 23.6
Infancy 36 50.0
> 1 year 13 18.1
Children presented with PUV various surgical modalities done to 
relieve the obstruction. Among 72 children 30 children had fulguration 
(41.7%), 31 children had Diversion & fulguration of valves (43.1%), 






Diversion & fulguration 31 43.1
Diversion 11 15.3
All 72 patients with PUV 7 children didn’t have UTI (9.7%) 
18 patients had one episode of UTI (25%) similarly 2 episodes in 27 
patients (37.5), 3 episodes 13 patients (18.1%) 4 episodes in 5 patients 
(6.9%), 5 episodes in 2 patients (2.8%).
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Table. 3







Among72 patients 35 patients (48.6%) had bilateral vesico ureteric 
reflux (VUR), 23 (31.9%) patients had No VUR & 14 patients (19.4%) 
had unilateral VUR either right or left. 
Table. 4 
VUR Frequency Percentage
No VUR 23 31.9
Unilateral 14 15.4
Bilateral 35 48.6
Risk factors for CRF 
1. Antenatel abnormal USG findings 
Table. 5 
AN USG FINDINGS CRF  
n (%)
No  CRF  
n (%)
Abnormal 2 (4.7) 10 (13.9) 
Normal 41 (95.3) 19 (65.5)
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AN USG findings were abnormal in 4.7% of patients with CRF 
& 13.9% of patients without CRF. AN diagnosis was associated with poor 
outcome with significant p value (p < 0.001).
2. Age at diagnosis 
Table. 6
Age at diagnosis CRF  
n (%)
No  CRF  
n (%)
< 1 yr 30 (69.8) 29 (100) 
> 1 yr 13 (30.2) 0 (0)
Age at diagnosis more than 1 year with associated with poor renal 
outcome with significant p value (p < 0.0001). 
Table. 7 
3. Bilateral VUR 
VUR CRF  
n (%)
No  CRF  
n (%)
Bilateral VUR 29 (67.4%) 6 (20.6)
No or Uniltateral 14 (32.6) 23 (79.3)
Bilateral vesico ureteric reflux was present in 29 patients (67.4%) 
was important  risk factor  for  chronic renal  failure  with odds ratio of  
8 with p value (p < 0.0001).  
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Recurrent UTI 20 (46.5) 0
No 23 (53.5) 29
Recurrent UTI is present is 20 patients (46.5%) with CRF, none of 
the patients in control groups had recurrent UTI with p value (<0.0001). 
5. Renal parenchymal damage by USG abdomen 
Table. 9 






Present 37 (86) 8 (38)
Absent 6 (14) 21 (62)
Renal  parenchymal  damage  was  present  in  37  patients  (82.2%) 
with CRF 8 patients without CRF (17.8%) among 43 patients with CRF 
37  patients  had  renal  parenchymal  damage  by  USG  with  p  value  
(p < 0.0001) (OR = 16).
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Present 31 (72.1) 1 (3.4) 
Absent 12 (27.9) 28 (96.6)
Persistence of upper tract dilatation after relief of obstruction was 
seen in 32 patients.  Among 43 patients with CRF 31 had a persistent 
upper tract dilation (72.1%) with p value (p < 0.0001) (OR = 72).
7. Timing of relief of obstruction 
Table. 11




> 1 yr 31 (72.1) 3 (10.3)
< 1 yr 12 (27.9) 26 
(89.7)
Relief of obstruction after 1 year of age was associated with poor 
renal outcome. Among 72 patients, 34 patients had surgery after 1 year. 
Among 43 patients with CRF 31 patients (72.1%) had surgery after 1 year 
with p value (p < 0.0001) (OR= 22).
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8. Absent “pop – off” Mechanism 
Table. 12




Yes 43 (100) 28 
(96.6)
No 0 (0) 1 (3.4)
Among 72 patients  1  patient  had peri  renal  urinoma.  “Pop off” 








Present 23 (53.5) 3 (10.3)
Absent 20 (46.5) 26 
(89.7)
Hypertension was present 26 patients among 72 patients with PUV 
among  CRF  patients  23  had  hypertension  (53.5%)  with  p  value  of  




Patients  with PUV there are  several  risk factors  associated with 
chronic renal failure. Factors important are antenatal diagnosis, B/L VUR, 
Recurrent  UTI,  renal  parenchymal  damage seen in ultra  sound,  age at 
diagnosis > 1 year, persistent dilatation after relief of obstruction absence 
of “pop-off” mechanism and hypertension.
Antenatal USG diagnosis was associated with significant of CRF 
with  p  value  <  0.001.  A similar  observation  was  already  been  made 
oliveira Eduaurdo A et al[13].
Bilateral vesicoureteric reflux  (VUR) was significantly associated 
with CRF with p value <0.0001. Similar observation was already been 
made by oliveira Eduaurdo A et al,  lopez Pereira P et al and kukreja et 
al[7,12,13].
Recurrent UTI was important risk factor for CRF was significant 
p value less than 0.0001. Similar observation was made by kukreja et al 
and Elisa Ylinen et al[8,12].
Renal parenchymal damage by USG Abdomen was associated with 
significant risk factor for CRF with p value < 0.0001. Similar observation 
was made by kukreja et al and lopez Pereira et al[7,12].
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Persistent dilated  system after surgery was associated with poor 
renal function with p value < 0.0001. Similar observation was made by 
kukreja et al & B Duel et al[12].
Absent “pop – off”  mechanism  was  associated  with  rapid 
progression of renal failure with p value < 0.22. Similarly Rittenberg  MH 
et  al[11] observed the protective factors  like (1)  VURD syndrome (2) 
bladder diverticula (3) urinary ascites associated with better preservation 
of renal function.
In the present study Hypertension was one of the significant risk 





PUV was the most common cause lower urinary tract obstruction 
and important cause of chronic renal failure in boys.
Degree  of obstruction, especially early in course of life adversely 
affect the renal function.
B/L VUR,  Recurrent  UTI,  Hypertension  and  renal  parenchymal 
damage by USG have a significant association with poor renal outcome. 
Absent  pop-  off  mechanism,  age  at  diagnosis  > 1 year  are  also 
cause for poor outcome need further study.
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ABBREVIATION
PUV - Posterior urethral valve 
CRF - Chronic Renal failure 
VUR - Vesico ureteric reflux
UTI - Urinary Tract Infection
VCUG - Voiding cysto urethrogram










Abd Distension /Fever/Vomoting 
Constipation/Failure to thrive / Refusal of feeds
Others.
Urological:
Stream Disturbances / retention / Dribbling 
Dysuria / Incontinence / Hematuria 
Polyuria / Hesitancy 
Examination :
Height & Weight 
Pallor
Blood Pressure
Abdominal Finding (Loin mass/palpablebladder/urinaryAscites)
Bony abnormalities 
Time of Ist Diagnosis : Antenatal / Newborn / Infant
Time of starting Treatment : <1year of age / >1 year of age
Type of Treatment 
Fulguration / Diversion procedure / Diversion → fulguration
Valve ablation / Reimplantation 
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Complications
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